

## NeuroMetrix to Present at the Marcum Microcap Conference on June 16, 2017

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, is scheduled to speak at the upcoming 2017 Marcum Microcap Conference at the Grand Hyatt Hotel in New York City. Dr. Gozani intends to provide an update on the Company's business activities including the Quell® Wearable Pain Relief Technology™.

The NeuroMetrix presentation is scheduled for Friday, June 16, 2017, at 10:00 a.m. EST. A live audio webcast will be available on the investor relations section of the corporate website - <http://www.NeuroMetrix.com/>. This webcast will be archived after the live event.

### About Quell

Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit [QuellRelief.com](http://QuellRelief.com) for more information.

### About Marcum Microcap Conference

The Marcum Microcap Conference was launched in 2012. The event has become a nationally recognized forum for publicly traded companies with less than \$500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities. More than 2,000 participants from all segments of the microcap market participate each year, including senior management, finance and legal executives, venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, buy- and sell-side analysts, and service providers to the microcap marketplace.

### About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit [NeuroMetrix.com](http://NeuroMetrix.com).

View source version on [businesswire.com](http://www.businesswire.com/news/home/20170608005004/en/): <http://www.businesswire.com/news/home/20170608005004/en/>

NeuroMetrix, Inc.  
Thomas T. Higgins, 781-314-2761  
SVP and Chief Financial Officer  
[neurometrix.ir@neurometrix.com](mailto:neurometrix.ir@neurometrix.com)

Source: NeuroMetrix, Inc.

News Provided by Acquire Media